Vismodegib
| Use attributes for filter ! | |
| Molar mass | 421. 3 g/mol |
|---|---|
| Bioavailability | 31. 8% |
| Formula | C19H14Cl2N2O3S |
| Trade name | Erivedge |
| Pronunciation | /ˌvɪsmoʊˈdɛɡɪb/ VIS-moh-DEG-ib |
| Other names | GDC-0449, RG-3616 |
| Music groups | Sonidegib |
| Vemurafenib | |
| Imiquimod | |
| Date of Reg. | |
| Date of Upd. | |
| ID | 2951293 |
About Vismodegib
Vismodegib is a drug for the treatment of basal-cell carcinoma. The approval of vismodegib on January 30, 2012, represents the first Hedgehog signaling pathway targeting agent to gain U. S. Food and Drug Administration approval.